FDA Approves FUROSCIX — scPharmaceuticals Inc., a wholly owned subsidiary of MannKind Corporation

scPharmaceuticals Inc., a subsidiary of MannKind Corporation, announced Thursday the FDA approved FUROSCIX (furosemide injection 80 mg/10 mL) for subcutaneous delivery. This approval positions the company to address the growing need for non-invasive diuretic therapy and creates a new commercial opportunity within the heart failure and chronic kidney disease markets.